Regular human insulin (1 IU ml−1) was administered by continuous intravenous infusion via syringe pumps.
The use of continuous intravenous regular human insulin (RHI) infusion is often necessary to achieve glycemic control in critically ill patients.
Currently available rapid-acting analogues (lispro, aspart and glulisine) achieve plasma peak concentrations about twice as high and within approximately half the time compared with regular human insulin thus closely mimicking the physiological insulin response to a meal.
An abbreviated modified minimal model test was performed, consisting of sequential blood samples for glucose and insulin assays, and intravenous infusions of 0.3 g/kg glucose and 0.02 U/kg regular human insulin.
For insulin tolerance tests, regular human insulin was administered intraperitoneally (0.75 mU/g) to mice after 4-h food deprivation, and blood glucose was measured at 0, 30, 60, 120 and 150 min after insulin injection.
This insulin was a re-constituted, lyophilised regular human insulin.
They are indeed absorbed more quickly than regular human insulin.
Short-acting analogs are superior to regular human insulin in CSII.
This is the main rationale underlying increasing use of U500 regular human insulin (6– 8).
To achieve final doses, regular human insulin and AspB10 were dissolved in 0.9% (wt/vol).
Regular human insulin was given at a dose of 0.10 unit/kg.
